Abstract
AbstractAlzheimer's disease (AD) is the leading cause of dementia, characterized by neuropathological features such as amyloid-β (Aβ) plaques, neurofibrillary tau tangles, and neurodegeneration. Immunotherapy offers a promising potentially disease-modifying treatment for AD. We review recent advances in AD immunotherapy, specifically focusing on Aβ, tau, and neuroinflammation-targeted approaches, and gain insights from randomized controlled trials to propose disease-modifying directions.
Publisher
Springer Science and Business Media LLC
Reference88 articles.
1. Ackley SF, Zimmerman SC, Brenowitz WD, et al. Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis. BMJ. 2021;372:n156.
2. Alhazmi HA, Albratty M. An update on the novel and approved drugs for Alzheimer disease. Saudi Pharm J. 2022;30(12):1755–64.
3. Ayalon G, Lee SH, Adolfsson O, et al. Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer’s disease. Sci Transl Med. 2021;13(593):eabb2639.
4. Boza-Serrano A, Ruiz R, Sanchez-Varo R, et al. Galectin-3, a novel endogenous TREM2 ligand, detrimentally regulates inflammatory response in Alzheimer’s disease. Acta Neuropathol. 2019;138(2):251–73.
5. Budd Haeberlein S, Aisen PS, Barkhof F, et al. Two randomized phase 3 studies of Aducanumab in Early Alzheimer’s disease. J Prev Alzheimers Dis. 2022;9(2):197–210.